We are happy to see so many great projects coming to Newark and we are proud to be a part of these exciting changes.
(PRWEB) December 04, 2014
On Wednesday, November 19th, 2014, Biotrial held a “Half Way There” event in Newark to celebrate the advancement of the construction of their Clinical Pharmacology Unit. The future site, located in the heart of the University Heights Science Park, attached to Rutgers/NJMS and the University Hospital, is the perfect location for performing Early Development Clinical Studies. Comprised of 60 000 sq. ft., this modern, state-of-the-art building will be completed and ready for occupation mid-2015, with the first Phase I and Bioequivalence Studies to be performed before the end of the year.
Attending the event were key figures from the surrounding institutions, financial partners, representatives from Newark City Business Development and the State of NJ, in addition to important members of the construction project team. Speakers included Dr. Joel Bloom, President, NJIT & Chairman, UHSP Board of Trustees, Dr. William Gause, Sr. Associate Dean, Research, Rutgers/NJMS, Dr. Debi Lazzarino, Assistant Dean for Research, Rutgers/NJMS, John Kinghorn, Investment Manager, Prudential Financial, James Crispino, President, Francis Cauffman and Paul Natoli, President, Joseph A. Natoli Construction.
The event was held at the International Center for Public Health, Biotrial’s neighbour who is directly adjacent to the future site. The Phase I Clinic, which will be located at 130 Norfolk St., has the Norfolk Street Station Light Rail stop at the north end of the property. Biotrial chose the site for its ease of access via public transportation as well as its close proximity to major roadways and Newark’s International Airport. These, in addition to the proximity to the University Hospital, Rutgers and NJMS, make the location an ideal one for the Clinical Research Facility.
In attendance for Biotrial was its General Manager, François Peaucelle. He expressed Biotrial’s gratitude to all of the partners, particularly those who have been instrumental in facilitating the choice of the location for the site. “We are happy to see so many great projects coming to Newark and we are proud to be a part of these exciting changes,” said Mr. Peaucelle, “On behalf of our entire company, we would like to thank everyone who has welcomed us here.” He went on to thank Biotrial’s clients, who “have trusted us for twenty-five years and are the main reason we decided to come to the US, enabling us to offer them the same high-quality services they know us for.”
Over the last few years, Biotrial has been developing important relationships with the University Hospital, Rutgers and NJMS. The collaboration between the company and institutions will be instrumental in building a medical research hub which will help attract R&D business to the area. Biotrial is looking forward to working closely with these institutions to offer highly scientific and medical expertise to its clients.
Founded in 1989 and specializing in Early Development, Biotrial provides solutions from in-vivo pharmacology through early clinical development to proof of concept, bringing a wealth of expertise to the study design process. With locations in Rennes, Mulhouse (Basel area), London, Montreal and Newark, Biotrial’s service lines include Non-Clinical Pharmacology, Phase I, Patient Studies, Bioanalysis, ECG & Imaging Core Lab (QT/QTc Trials, Psychometric Testing, Imaging, EEG/PSG Assessment), Oncology, Data Management, Biostatistics, Medical Writing, Quality Assurance & Regulatory Affairs.
For more information, visit http://www.biotrial.com